Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) announced on June 2 that the US Food and Drug Administration, FDA, granted Expanded Access authorization for its Cancer BioShield platform, anchored by ANKTIVA, for the treatment of lymphopenia. Lymphopenia is a life-threatening immune deficiency induced by radiotherapy, chemotherapy, and immunotherapy.

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

Following the announcement, H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on ImmunityBio Inc. (NASDAQ:IBRX) on June 4 and set a price target of $8.00. The analyst reasoned that the Cancer BioShield platform and the company’s therapies hold the potential to address immune collapse in complex cancer cases, bringing a positive light to its operations.

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.